7 and to inhibit endothelium-dependent arterial relaxation (EDR). 8 We have reported that Ox-LDL inhibits EDR of rabbit aortas in response to endothelial surface receptor-mediated agonists (acetylcholine, ATP, or substance P) but not to calcium ionophore A23187, which bypasses a receptordependent membrane regulation. 8 We have also clarified that lysophosphatidylcholine (lysoPC), which is abundant in Ox-LDL, is primarily responsible for the inhibitory action of Ox-LDL on EDR. 8 Although one may expect that Ox-LDL could interfere with endothelial surface receptor-mediated signaling pathways, there are few reports focusing on the cell signal transduction underlying the mechanism of inhibitory effect of Ox-LDL on EDR.
LysoPC is known to regulate a number of membraneassociated enzymes such as guanylyl and adenyh/1 cyclases, 9 GTPase, 10 or protein kinase C (PKC), 11 all of which play an important role in the intracellular signaling pathways. Recently, we have shown that lysoPC inhibits surface receptor-mediated intracellular signals in cultured human endothelial cells and that PKC activation by lysoPC negatively regulates receptor-coupled signal transduction. 12 In the present study, on the basis of our previous observation, we further determined whether the modulation of PKC activity may be involved in the EDR inhibition by Ox-LDL.
Methods

LDL Preparations
LDL was isolated by sequential ultracentrifugation (1.019<d< 1.063) from fresh human plasma after addition of 1 mg/mL EDTA (native LDL), sterilized by filtration (filter pore size, 0.22 ^m; Millipore, Bedford, Mass), and then stored in a sterile tube at 4°C in darkness. Just before modification, LDL was extensively dialyzed against phosphate-buffered saline (PBS; 137 mmol/L NaCl, 2.7 mmol/L KC1, 1.4 mmol/L NaH 2 PO 4 , and 4.3 mmol/L Na 2 HPO 4 , pH 7.4) under a nitrogen stream for 24 hours at 4°C.
Endothelial cells harvested from porcine aorta were cloned and maintained in Dulbecco's modified Eagle's medium supplemented with 10% fetal calf serum at 37°C under a humidified atmosphere of 5% CO 2 -95% air. Confluent cultures of the cells exhibited the typical cobblestone pattern, and most of the cells had factor VHI-related antigen as detected by indirect immunofluorescence. 13 Ox-LDL was prepared by incubating LDL (150 fig protein/mL) with confluent cultured porcine endothelial cells (endothelial cell-modified LDL [EC-LDL]) in serum-free F-10 medium under sterile conditions as reported elsewhere. 8 Thiobarbituric acid-reactive substances in the culture medium after incubation of native LDL with endothelial cells averaged 2.4+0.3 nmol malondialdehyde equivaJents/mL culture medium. After 24 hours of incubation, EC-LDL in the medium was reisolated by ultracentrifugation at d=1.21 for 24 hours, sterilized by filtration, and used for the bioassay experiments within 3 days. The electrophoretic mobility of EC-LDL on the agarose gel 14 related to that of native LDL was 1.7±0.1-fold. Just before being used for the bioassay experiments, stored native LDL and EC-LDL were extensively dialyzed against PBS containing 50 /i.mol/L EDTA and 20 jtmol/L butylated hydroxytoluene (BHT) for 24 hours at 4°C in separate bottles. No LDL preparation was contaminated by endotoxin (less than 10 pg/mg LDL protein) as assessed by the chromogenic limulus lysate test (Toxicolor test, Seikagaku Kogyo, Tokyo, Japan) as described in our previous article. 15 To determine whether lysoPC is responsible for the biological effects of EC-LDL, aliquots of EC-LDL (4 mg protein/mL) were incubated for 2 hours at 37°C with phospholipase B (4 U/mL) in PBS. 16 The effect of phospholipase B-treated EC-LDL was always compared with the same batch of EC-LDL treated without phospholipase B but in the same preparative manipulation as phospholipase B-treated EC-LDL. Protein concentration of LDL was determined by the method of LowTy et al. 17 
Organ Chamber Experiments With Porcine Coronary Arteries
The left circumflex coronary arteries were isolated from domestic Yorkshire pigs within 10 minutes after death. All experiments were in accordance with the guidelines on experimental animals issued by our institution. These arteries were dissected free from adherent connective tissues and cut into ring segments 4 mm wide. During the preparation, any contacts with the luminal surface were avoided to preserve endothelial cell integrity.
Each segment was vertically suspended between stainless steel hooks and incubated in the organ chamber with Krebs-Henseleit solution. The solution was aerated with 15% 0^5 % CO2-80% N 2 (Po^lOO mm Hg) and maintained at 37°C and pH 7.4. (20 fimolfL) and BHT (20 /xmol/L) were included in the buffer to avoid intraexperimental auto-oxidation of lipoprotein. The resting tension was adjusted to 3 g in porcine coronary arteries, and changes of isometric tension were monitored using a force transducer (UL-20GR; Minebea, Tokyo, Japan) and recorded by an ink-writing pen recorder (SR6211; Graphtec, Tokyo, Japan). Before the start of experiments, all ring segments were allowed to equilibrate for 2 hours, during which the incubation buffer was replaced every 20 minutes.
After the equilibration period, the contractile response to potassium chloride (60 mmol/L) was first obtained to confirm the contractile response of the vascular smooth muscle. The segments were then washed repeatedly and equilibrated for 30 minutes before the start of the next protocol. Arterial rings were exposed to LDL preparations (100 to 300 ng LDL protein/mL), phospholipids (10 /xmol/L), or phorbol 12-myristate 13-acetate (PMA; 1 nmol/L) for 40 minutes in the presence or absence of staurosporine (20 nmol/L) or calphostin C (5 nmol/L). After the incubation, the rings were washed repeatedly. They were precontracted with 30 fimo\/L prostaglandin F 2a (PGF^) for the porcine coronary arteries and tested with various vasodilators as indicated. Control studies were performed to expose the coronary arteries in the organ chamber to the same volume of PBS (less than 1% of chamber volume) and to the same period of incubation as the studies that examined the arteries exposed to EC-LDL or lysoPC. In some experiments, the rings were pretreated with indomethacin (10 /xmol/L) for 30 minutes and then exposed to LDLs or phospholipids for an additional 40 minutes. Indomethacin remained present in the organ bath solution during the exposure of the rings to LDLs or phospholipids.
The extent of agonist-induced relaxation was expressed as a percentage of the precontraction value evoked by PGF^.
Organ Chamber Experiments With Rabbit Aortas
Aortic strips, as another arterial source, were obtained from male New Zealand White rabbits weighing 2.5 to 3.0 kg. The rabbit aortic strips of 4-mm width were prepared in a similar manner to the porcine coronary arteries, as shown in a previous article. 8 25 .0; glucose, 5.0; EDTA, 0.02; and BHT, 0.02. The aortic strips were exposed to LDL preparations or phospholipids for 2 hours. Control studies were performed to expose the rabbit aortas in the organ chamber to the same volume of PBS (less than 1% of chamber volume) and to the same period of incubation as the studies that examined the aortas exposed to EC-LDL or lysoPC. Thereafter, the strips were repeatedly washed, precontracted with phenylephrine (1 j i mol/L), and then tested with various vasodilators.
The extent of agonist-induced relaxation was expressed as a percentage of the precontraction value evoked by phenylephrine.
Measurement of LysoPC Content in LDL Preparations
The method for measurement of lysoPC content in LDL preparations was described previously. 8 Briefly, lipids were extracted from LDL preparations by the method of Bligh and Dyer 18 and were then analyzed by thin-layer chromatography (TLC) using silica gel G plates with a solvent mixture containing chloroformmethanol-water (25:10:1, vol/vol/vol). The lipid band representing lysoPC was eluted with a solvent mixture containing chlorofonn-methanol-water (5:5:1, vol/vol/ vol), and phospholipid phosphorus in the eluate was measured by the Bartlett procedure 8 with a phospholipid assay kit (Wako Chemical, Osaka, Japan).
Transfer of LysoPC From EC-LDL to Endothelial Cells
The sonicated [ 6 cpm/mg LDL protein). Cultured confluent porcine endothelial cells on 100-mm dishes (5x 10 d cells) were incubated for 2 hours in 7 mL protein-free culture medium containing the various concentrations of EC-LDL (10 to 100 ^tg protein/mL) labeled with [ I4 C]tysoPC. After the incubation, the endothelial cells were quickly washed four times in cold PBS and harvested by a scraper on ice. The cells were homogenized and suspended in a tris(hydroxymethyl)aminomethane (Tris) buffer (25 mmol/L, pH 7.5) containing EDTA (1 mmol/L). The suspension was centrifuged at 100 OOOg for 1 hour to collect the supernatant as a cytosol and the pellet as a particulate fraction. Then the radioactivity of the cytosol and particulate fractions was counted by scintillation spectrometry. Lipids in some aliquots of the pellet were extracted by the method of Bligh and Dyer. 18 The extracted lipids were analyzed by using TLC as described above. The lipid band representing each of the phospholipids was scraped and eluted, and the radioactivity in each of the phospholipids was counted by scintillation spectrometry.
Assay of PKC Purified From Porcine Endothelial Cells
Confluent cultures of the endothelial cells were washed three times in cold PBS, quickly frozen by liquid nitrogen, and homogenized with the buffer (20 mmol/L Tris, pH 7.5, 2 mmol/L EDTA, 2 mmol/L EGTA, and 1 mmol/L dithiothreitol) containing protease inhibitors (100 jAmol/L leupeptin, 37 /imol/L pepstatin A, and 0.05 mg/mL aprotinin). PKC was purified from the cytosolic fraction of endothelial cells by the column chromatography of a DEAE-Sephacel. 19 The standard reagent mixture for assay of PKC activity, based on the phosphorylation of synthetic peptide (PKC substrate; VRKRTLRRL), 20 contained 50 mmol/L A/-2-hydroxyethylpiperazine-W-2-ethanesulfonic acid, pH 7.5, 10 mmol/L magnesium acetate, 500 ^unol/L CaCl 2 , 0.1 mmol/L [>-3f P]ATP (3000 to 5000 cpm/pmol) (Du PontNew England Nuclear), 50 jig/mL phosphatidylserine, 5 /xg/mL diolein, 3 /xmol/L mastoparan (a peptide inhibitor for Ca 2+ /calmodulin-dependent protein kinase), 5 jimol/L cAMP-dependent protein kinase inhibitor (PKI-tide) (a peptide inhibitor for cAMP-dependent protein kinase), and 40 /xmol/L PKC substrate in a final volume of 25 fiL. The reaction was initiated by the addition of 5 fiL purified PKC to the standard reagent mixture containing the various concentrations of lysoPC. After an incubation of 8 minutes at 30°C, 15 jtL of the aliquots was spotted on phosphocellulose paper (Whatman P-81) squares to measure the PKC activity. 21 The phosphatidylserine-dependent and diolein-dependent PKC activities were calculated as the difference between the total count in the standard reagent mixture and the background count in the reagent mixture without phosphatidylserine and diolein and with a peptide inhibitor for PKC (PKC.M, 2 jimol/L). 22 In the experiments for the assay of PKC activity, protein concentration was determined by the method of Bradford 23 using bovine serum albumin as a standard.
Drugs
All reagents for the cell cultures were obtained from GIBCO. The following drugs and chemicals were obtained from the indicated sources: thrombin, calcium ionophore A23187, PMA, palmitoyl lysoPC, dipalmitoyl phosphatidylcholine (PC), indomethacin, sodium nitroprusside, phenylephrine, phosphatidylserine, 13 -diolein, and phospholipase B (Sigma Chemical Co, St Louis, Mo); staurosporine and calphostin C (Kyowa-Hakko, Tokyo, Japan); PGFj,, (Ono Pharmaceutical, Osaka, Japan); PKC substrate, PKQg.*, and PKI-tide (Bachem, Torrance, Calif); and mastoparan (Peptide Institute Inc, Osaka, Japan). Phospholipids were sonicated in PBS with a Bronson sonicator before use. A23187, PMA, staurosporine, and calphostin C were dissolved in dimethyl sulfoxide; the total volume of dimethyl sulfoxide as a drug vehicle in the final solution was less than 0.1% (vol/vol). The indomethacin solution was prepared in an equimolar concentration of Na 2 CO3.
Data Analysis
All data are expressed as mean±SEM in the text, figures, and tables. Statistical evaluation of the data was performed by Student's t test for unpaired observations. When more than three groups were compared, an analysis 0f variance was used. If a significant F value was found, a modified t test (Tukey's) was used for statistical evaluation between each group. Differences between values were considered to be statistically significant when P<.05.
Results
Effects of EC-LDL or LysoPC on Relaxation of Porcine Coronary Arteries
Incubation with EC-LDL (100 fig protein/mL) significantly inhibited the relaxation in response to graded concentrations of thrombin (0.001 to 1.0 U/mL) in porcine coronary arteries, whereas native LDL (up to 300 /ig protein/mL) had no inhibitory effect on the relaxation (Fig 1) . The vasorelaxation in response to calcium ionophore A23187 (1 to 100 nmol/L) was completely preserved after the incubation with native LDL or EC-LDL (Fig 1) . Pretreatment with phospholipase B reduced lysoPC content in EC-LDL to the level of native LDL (Fig  2) and at the same time attenuated the inhibitory effect of EC-LDL on thrombin-induced vasorelaxation (Fig 1) . Incubation with synthetic palmitoyl fysoPC (10 /xmol/L) inhibited the vasorelaxation in response to thrombin but not to calcium ionophore A23187, whereas dipalmitoyl PC (10 jimol/L) had no effect on either thrombin-or A23187-induced vasorelaxation. The maximal relaxations in response to thrombin and A23187 were as follows: control, 84.3+5.5% (n=7) and 102.0±1.7% (n=8); lysoPC, 19.5+6.7% (n=10,/ > <.01 versus control) and 100.9±0.6%
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FIG 3. Line graph showing effect of endothelial cell-modified low-density lipoprotein (EC-LDL) (100 fig protein/mL) on the relaxations of porcine coronary arteries in response to graded concentrations ofthrombin in the presence or absence of staurosporine (20 nmol/L). Coincubation with staurosporine (EC-LDL+Staurosporine, n=8)prevented the inhibitory effect of EC-LDL on the vasorelaxation. *?<.O5, **?<.01 vs control (n=10); tP<.05, t t P < 01 vs EC-LDL (n=8).
cin+lysoPC, 24.7±15.7% [n=6] versus lysoPC alone, 19.5±6.7% [n=6], P=NS).
To determine the possible involvement of PKC in the inhibitory effects of EC-LDL or lysoPC on vasorelaxation, we examined whether treatment of the arteries with staurosporine or calphostin C, the potent inhibitors of PKC, affected the inhibitory effects of EC-LDL or lysoPC. Coincubation with staurosporine (20 nmol/L) significantly attenuated the inhibitory effects of both EC-LDL and lysoPC on the vasorelaxation in response to thrombin (Figs 3 and 4) . Coincubation with calphostin C (5 nmol/L) also significantly prevented the EC-LDL-and lysoPC-induced inhibition of vasorelaxation in response to thrombin (Table 1) . Incubation with PMA (1 nmol/L), a specific activator of PKC, caused the inhibition of vasorelaxation in response to thrombin but not in response to calcium ionophore A23187 (Fig 5) , which closely resembled the actions exerted by EC-LDL and lysoPC. Coincubation with staurosporine attenuated the inhibitory effect of PMA on the vasorelaxation in response to thrombin (Fig 5) . Also, coincubation with calphostin C prevented the inhibitory effect of PMA on the thrombin-induced vasorelaxation (Table 1) . These results suggested that PKC activation may at least in part be responsible for the inhibitory effect of EC-LDL or lysoPC on thrombin-induced vasorelaxation.
Incubation with LDL preparations or phospholipids had no significant influences on the PGF 2a -induced precontraction values compared with control values (Table 2) . Incubation with staurosporine alone exerted no significant effect on the vasorelaxation in response to thrombin (maximal relaxation: control, 77.6±5.6% [n=8]; staurosporine, 75.1±4.2% [n=7]; />=NS). Incubation with calphostin C alone exerted no effect on the thrombin-induced vasorelaxation ( 
Effects of EC-LDL or LysoPC on Relaxation of Rabbit Aortas
To examine whether species differences may alter the effect of staurosporine, rabbit aortic strips were used to examine the effect of staurosporine on the inhibitory actions of EC-LDL and lysoPC. Incubations with EC-LDL (100 ng protein/mL) and lysoPC (10 jimol/L) significantly inhibited vasorelaxation in response to acetylcholine (0.01 to 10 /xmol/L; Figs 6 and 7) and as previously reported. 8 The inhibitory effects of EC-LDL or rysoPC on the vasorelaxation in response to acetyl- 
Transfer of LysoPC From EC-LDL to Endothelial Cells
The cytosolic and particulate fractions prepared from the cultured endothelial cells acquired radioactivity after incubation of the cells with [ (Table 3) . During the 2-hour incubation, 12.0±2.9% of the lysoPC in EC-LDL was transferred to endothelial cells. Of the transferred lysoPC, 82.8 ±2.7% was detected in the particulate fraction and 17.2±2.7% was found in the cytosolic fraction. To exclude the possibility of the transfer of lysoPC from the pellet to the cytosol during cell fractionation, the nonlabeled cytosol from endothelial cells was mixed with the particulate containing [ 14 C]lysoPC and was then separated by the same procedure as described above. The cytosolic fraction gained less than 3% of the radioactivity of the particulate (n=3).
Analysis of the lipid extracts from the particulate fraction using TLC showed that 28% of total radioactivity remained in the lysoPC band and 11% was present in the PC band. The rest of the radioactivity was in the solvent front.
Effects of LysoPC on PKC Activity
In the experiment using the PKC purified from porcine endothelial cells, lysoPC synergistically enhanced the PKC activity with phosphatidylserine and diolein at the lower concentrations, which ranged from 0.5 to 3.0 /imol/L (Fig 8) . In contrast, lysoPC suppressed the activity at the higher concentrations, which ranged from 5 to 10 /imol/L (Fig 8) . LysoPC did not affect the activity in the absence of phosphatidylserine and diolein (control, 78±12; 0.5 ^mol/L lysoPC, 75±12; 5 ^mol/L lysoPC, 72±7; values are given in picomole/milligram protein per minute; / ) =NS). Each experiment was repeated four times.
Discussion
The present study demonstrated that EC-LDL inhibited EDR in response to thrombin and acetylcholine. Both thrombin and acetylcholine are vasodilator agonists that act through endothelial surface receptors. The incubation with EC-LDL had no influence on the EDR in response to calcium ionophore A23187, which is an endothelium-dependent vasodilator that bypasses a receptor-coupled membrane regulation. 24 Vasorelaxation in response to sodium nitroprusside, an endotheliumindependent vasodilator, was completely preserved after the incubation with EC-LDL. Furthermore, the study using electron microscopy showed that the morphological appearance of the endothelium of the arteries was well preserved after exposure to EC-LDL. These results indicated that the inhibition of EDR is not due to the nonspecific cytotoxic effects of EC-LDL on endothelium but that the surface receptor-mediated EDR is selectively inhibited by EC-LDL.
Oxidative modification of LDL is associated with the substantial hydrolysis of PC to lysoPC. 125 We demonstrated that the decreased content of h/soPC in EC-LDL after treatment with phospholipase B was associated with attenuation of the inhibitory effect of EC-LDL on EDR in response to thrombin. The present study also demonstrated that the sonicated lysoPC but not PC exerted an inhibitory effect on the EDR in response to thrombin and acetylcholine, mimicking those exhibited by EC-LDL. These results suggested that lysoPC is primarily responsible for the inhibitory effect of EC-LDL on EDR in response to thrombin or acetylcholine. LysoPC is transferable to accessible membranes or macromolecular acceptors through the aqueous phase. 26 The present study showed that lysoPC was transferred from EC-LDL to endothelial cell membrane and cytosol. These results indicated that lysoPC, which is transferred from EC-LDL to endothelial cells, may be involved in the mechanism of the inhibitory effect of EC-LDL on the EDR in response to endothelial surface receptor-mediated agonists such as thrombin or acetylcholine.
PKC has a crucial role in the signal transduction pathways involving functional alterations of various cells. 27 Activated PKC is also known to inhibit the cell surface receptor-coupled signal transduction in many types of cells, including endothelial cells. 2830 Recently, we clearly showed that lysoPC inhibits thrombin-or histamine-mediated intracellular signals and that PKC activation is involved in the negative regulation by lysoPC. 12 The present study demonstrated that staurosporine or calphostin C, the potent inhibitors of PKC, 31 -32 prevented the inhibition of EDR by EC-LDL or h/soPC in porcine coronary arteries and rabbit aortas. PMA, a specific activator of PKC, 33 inhibited EDR in response to thrombin but not to A23187, and its inhibitory effect was prevented by staurosporine and calphostin C, which reflected the similar actions obtained by EC-LDL or lysoPC. As shown in the present study, lysoPC at the lower concentration stimulates the activity of PKC purified from porcine endothelial cells. Furthermore, we have reported 12 that in intact endothelial cells lysoPC increases the membrane-associated PKC activity and decreases the cytosolic PKC activity. Thus, at the concentrations of EC-LDL and lysoPC used in the present organ chamber experiments, PKC activated by lysoPC inhibited endothelial surface receptor-coupled signal transduction and at least in part may be responsible for the inhibitory effect of EC-LDL on EDR in response to surface receptor-mediated agonists. However, the present study showed that lysoPC modulates the activity of purified PKC in a biphasic manner, ie, lower concentrations of lysoPC activated the PKC activity, whereas higher concentrations of lysoPC suppressed the activity. We also demonstrated that approximately 1.8 junol lysoPC was transferred from EC-LDL (100 jig protein/mL) in 7 mL serum-free medium to endothelial cells (5xl0 6 cells). However, the concentration of the transferred lysoPC in the subcellular fractions of the intact endothelial cells remains undetermined. Therefore, it remains unknown whether the concentration of the transferred lysoPC is comparable to the concentration of lysoPC that activated PKC in the test tube experiment in the present study. The intracellular process of PKC activation by EC-LDL and lysoPC and its endogenous substrates in the intact endothelial cells are now under investigation in our laboratory.
A recent article shows that stimulation of PKC in endothelial cells induces production of vasoconstrictive prostanoids that may counteract EDR. 34 However, this possibility is less likely in this study because EDR was tested after repeated washing at the end of the incubation and coincubation with indomethacin had no effects on inhibition of EDR by EC-LDL or lysoPC.
LysoPC is also known to regulate other membraneassociated enzymes such as guanylyl and adenylyl cyclase 9 or GTPase, 10 all of which may play an important role in intracellular signaling pathways. We need further studies to clarify whether the effects of lysoPC on the other membrane-associated enzymes may be involved in the inhibition of surface receptor-mediated EDR by Ox-LDL.
In conclusion, PKC activated by lysoPC, which is transferred from EC-LDL to endothelial cells, may play
